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Introduction
Human papillomaviruses (HPV) are double-stranded DNA viruses infecting epithelial cells of skin and mucosa (1) . Mucosal HPV genotypes are divided into low-risk (lrHPV) and high-risk (hrHPV) groups based on their association with severe disease or cancer (1) . HPV is best known for its association with cervical cancer and highgrade cervical lesions (CIN2 + ), which are caused by a persistent hrHPV infection (2, 3) . In cervical cancer screening programs the cytology-based Papanicolaou (Pap) test has been traditionally used. Recently, it has been shown that hrHPV testing can also be used in primary cervical cancer screening of 30-year-old and older women, and also as a triage test of atypical squamous cells of undetermined significance (ASC-US) cytology, as well as test of cure after treatment of cervical intraepithelial neoplasia (CIN) (4, 5) . HrHPV testing has also proven more sensitive than the Pap test (6) (7) (8) and has a higher negative predictive value, which means that a negative HPV test result indicates a very low risk of developing cervical cancer within the next 5-10 years (9) (10) (11) (12) . The challenge with HPV testing is the lower specificity as compared with cytology in the age group below 30 years of age (6) .
In this study we compared the performance of two commercial hrHPV assays in the detection of high-grade cervical lesions and cancer: Hybrid Capture 2 (HC2; Qiagen, Gaithersburg, MD, USA) and Aptima HPV Assay (Hologic, Inc., Marlborough, MA, USA). Test performance was compared in a study population of a colposcopy clinic, comprising women whose cytological and histological findings vary from normal to LSIL or CIN3, respectively. No specific selection criteria were applied; instead we wanted to evaluate the tests in the practical settings of a standard colposcopy clinic, and among the regular patient flow where the use of hrHPV testing could be considered.
Material and methods
Altogether, 481 paired cervical cell samples were collected from Finnish women who visited the colposcopy clinic at the Department of Gynecology at the Helsinki University Jorvi Hospital between September 2013 and March 2014. The cohort comprised women with recent cervical findings as well as those who had already been treated and monitored for a longer period of time -representing a typical population attending a tertiary-care colposcopy clinic. Two separate cell samples were collected, a few seconds apart, using a Digene Cervical Sampler and Specimen Transport device (Qiagen) and Aptima Cervical Specimen Collection and Transport device (Hologic). The samples were taken in random order, and during the same visit cytological and/or histological samples were also collected based on clinical decision, independent of study sample collection. Conventional Papanicolaou test was used for cytology. All cytological and histological analyses were carried out at the Department of Pathology of Helsinki University Hospital Laboratory. The Ethics Committee of the Hospital District of Helsinki and Uusimaa approved the collection of samples for this study on 29 April 2013 (reference number 130/13/03/03/2013) and written informed consent was obtained from all patients.
Cervical samples were tested using two different methods: the manual Hybrid Capture 2 (HC2) HPV DNA test (Qiagen),which detects the DNA of 13 different hrHPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) and the Aptima HPV Assay (Hologic) with the fully automated Panther system (Hologic),which detects the mRNA of 14 different hrHPV types (those mentioned above and additionally HPV 66). Both assays are FDA-approved and CE-IVD-marked. The assays were performed according to the manufacturer's instructions. All samples found positive with either assay were also genotyped using the Aptima HPV 16 18/45 Genotype Assay (Hologic). To further verify test performance in our hands, a subset of HPV negative samples was examined with the genotyping assay as well. All HPV analyses were carried out at the Department of Virology and Immunology of Helsinki University Hospital Laboratory. In the Aptima assay, the signal to cut-off (S/CO) value of ≥0.5 was interpreted as positive. In the HC2 assay, the limit of positivity was the relative light unit per cut-off (RLU/CO) value ≥1. All HC2 samples with initial RLU/CO values between 0.8 and 1.5 were retested once or twice to confirm the result, according to the manufacturer's recommendation. The performance of the two hrHPV assays as well as cytology in the detection of histologically verifiable diseases was assessed. Samples for HPV testing, cytology and histology were collected at the same visit.
Statistical analyses
Data analysis was performed using CIN2 or more severe lesion (CIN2 + ) as a cut-off for presence of the disease. The results were also stratified according to patient age, reason for colposcopy and cytological status. For HC2, Aptima and cytology sensitivity, specificity, predictive values and their 95.0% confidence intervals (CI) were calculated assuming binomial distribution of the test's results. The p-values for comparing sensitivity and specificity of tests were calculated using McNemar's test (13) . The agreement between the two hrHPV assays was evaluated by Kappa statistics (14) . All statistical analyses were performed with STATA software (StataCorp 2013, Stata Statistical Software: release 13.1, College Station, TX, USA).
Results
The age of the patients ranged from 18 to 86 years. age. Of all HPV-tested women, 196 (40.8%) attended HPV sampling because of an abnormal Pap test, and a biopsy had been taken from 197 women (41.0%) on the preceding visit before HPV sampling due to earlier suspicion of HPV-related disease. For the remaining 87 women (18.1%) the reason for HPV sampling was continuing surveillance because of previous findings, another specified reason (for example, pain in lower abdomen or bleeding), or the reason was not clearly specified in the patient registry. The time between the preceding visit and HPV sampling ranged from less than 1 month to 1 year.
Altogether, 481 paired samples were analyzed using both Aptima and HC2 methods. One Aptima sample was insufficient and was thus excluded from the analysis, leaving 480 paired samples for the analysis. In total, 202 samples (42.1%) tested positive using the HC2 method and 206 (42.9%) using the Aptima method (Table 1 ). There were 34 (7.1%) discrepant samples of which 15 were HC2-positive but Aptima-negative, and 19 Aptima-positive but HC2-negative ( Table 1 ). The overall agreement between the assays was 92.9% (Kappa coefficient of 0.855).
HrHPV assay results as well as sensitivities, specificities, and positive and negative predictive values within histological groups are presented in Tables 2 and 3 . The sensitivity and specificity to detect CIN2 + was 92.5 and 58.2% for HC2, and 94.0 and 59.3% for Aptima, respectively. No significant differences in test performance between the two hrHPV assays were found (p-values >0.5). Specifically, five CIN2 cases (14.3%) remained hrHPV-negative using the HC2 assay and four (11.4%) using the Aptima assay. Importantly, all CIN3 cases (n = 30) and the two carcinomas found were detected with both hrHPV assays. Of the samples giving discrepant results with the two hrHPV assays, six had normal histology, 15 had CIN1 grade lesions, three had CIN2 grade lesions and 10 had no histological reference. Of the three discrepant CIN2 cases, one was positive only with HC2 and two with Aptima.
Results were also analyzed separately according to the reason for colposcopy referral ( Table 4 ). The study population was divided into three groups based on the preceding visit before HPV sampling. These groups were: (1) patients who had a Pap test suggestive of cervical lesion; (2) patients who had a treatment or control visit at which histology was obtained; (3) other patients (longterm follow up with normal findings, specified reasons such as bleeding or pain in lower abdomen, the preceding visit was more than 1 year before HPV sampling, or no data were available about the previous visit). In every group the predictive values were the same for both assays or slightly higher for Aptima. Aptima was also 2.1 percentage points more specific when the reason for colposcopy was a previous Pap test suggestive of cervical lesion, and 8.4 percentage points more sensitive for women whose histological status had been confirmed on the preceding visit. However, these differences were not statistically significant (p-values >0.5). In the group of other reasons for colposcopy, the performance was identical for both assays and both sensitivity and negative predictive values reached 100.0%.
HrHPV results with cytological findings at the HPV sampling visit are shown in Table 5 . The rates of positive and negative hrHPV findings in the various cytological groups were similar for both hrHPV assays. The positivity rate increased from 20.7 to 95.0% from normal towards ASC-H and more severe findings. The performance of hrHPV assays was also similar when compared with cytological findings at the HPV sampling visit (Table 6) . Among normal and non-severe (ASC-US and LSIL) findings, both the sensitivity and the specificity were slightly higher for Aptima but the differences were not statistically significant (p-values >0.5). In ASC-H and more severe findings, the sensitivity was 100.0% and the specificity 15.8% for both assays. Sensitivity, specificity, and positive and negative predictive values with 95.0% CI for the Pap test in the detection of CIN2 + are shown in Supporting Information Table S1 . The sensitivity and specificity of cytology in detecting CIN2 + was 86.2 and 52.0% when using ASC-US as a cutoff, and 75.4 and 72.7% when LSIL was used as a cut-off. HrHPV testing was found more sensitive (p-value 0.003 for Aptima and 0.002 for HC2) in detecting CIN2 + than cytology when LSIL was used as a cut-off. However, cytology was more specific (p-value <0.001 for both assays), but at the cost of decreased sensitivity. Although both hrHPV assays demonstrated slightly higher sensitivity and specificity in detecting CIN2
+ than cytology when ASC-US was used as a cut-off, only the better specificity of the Aptima assay was statistically significant (p-values for sensitivity: 0.132 for Aptima and 0.206 for HC2, and for specificity: 0.033 for Aptima and 0.077 for HC2).
Test parameters were also calculated separately for two age groups, <30 and ≥30 years (Supporting Information Tables S1 and S2). The sensitivities for hrHPV assays were very similar between the two age groups but were slightly higher in the younger age group (Table S2) . For the Aptima assay the sensitivity reached 100.0% in women younger than 30. As for Pap test, the sensitivities were higher in the older age group and the differences were more evident (Table S1 ). For both hrHPV and Pap tests there were clear differences in specificities between the age groups and for each testing method the specificities were higher in women aged 30 or older. The negative predictive values (NPV) for detecting CIN2 + were higher for hrHPV assays than for the Pap test in all age groups. The NPVs for the Pap test using either ASC-US or LSIL cut-off were more than 12 percentage points lower in women below 30 years than in the older age group. For hrHPV assays there were only minor differences between age groups and the NPV of the Aptima assay reached 100.0% in the younger age group. The positive predictive values (PPV) in detecting CIN2 + remained fairly low for both hrHPV and Pap tests in all age groups.
Aptima genotyping assay was performed for all samples found positive using either hrHPV assay. Of all samples in this study, 10.2% were positive for HPV16 and only 4.6% for HPV18/45 (Supporting Information Table S3 ). One sample which was found positive in both Aptima and HC2 assays tested positive for both HPV16 and HPV18/45. The samples that were initially Aptimapositive but HC2-negative (n = 19) included one sample which was positive for HPV18/45, two positive for HPV16, and 16 positive for other hrHPV genotypes. All initially Aptima-negative but HC2-positive samples (n = 15) and the tested subset of samples that were initially negative with both methods (n = 55) remained negative in the genotyping assay.
HrHPV was found in 88.6% of CIN2 grade lesions (Table S3 ). The majority (48.6%) were hrHPV types other than 16 or 18/45, whereas HPV16 was found in 31.4% and HPV18/45 in 8.6% of CIN2 lesions, respectively. High-risk HPV was found in all CIN3 lesions: HPV16 was detected in 40.0%, HPV18/45 in 13.3%, and other hrHPV types in 46.7% of CIN3 lesions. Of the two carcinomas, one was positive for HPV16 and the other 
Discussion
The purpose of this study was to assess the performance of HC2 and Aptima hrHPV assays in the detection of high-grade cervical epithelial lesions among the routine patient flow at a tertiary-care colposcopy clinic. Cytological samples were assessed as well, and all results were compared with histological findings from biopsies collected at the same visit. Similar sensitivity, specificity, PPV and NPV were shown for both hrHPV assays. However, a significant improvement in sensitivity was obtained as compared with the conventional Pap test. Because both hrHPV assays were found to perform equally well, the individual requirements of the laboratory may be decisive in choosing the appropriate hrHPV assay.
The overall agreement between the hrHPV assays was very high (92.9%) and similar rates have been reported in other studies, where the overall agreement has been between 88 and 97% (15) (16) (17) . Overall, both hrHPV assays performed with higher sensitivity and higher NPV than conventional cytology. Improvement of assay sensitivity often brings about an increasing rate of false-positive findings, decreasing test specificity. This is particularly evident in hrHPV testing, where test positivity is common in the absence of disease, especially in younger age groups. Many HPV infections among young women are transient, and the proportion of persistent infections increases in older age groups (18) . In the case of mild disease, spontaneous clearance often takes place (19, 20) . As seen in our study, hrHPV testing is highly sensitive in young women but the specificity is clearly lower than in older age groups. Test specificity increases among women more than 30 years of age, whose HPV infections are more likely to be persistent and to cause disease. Still, among younger women the very high sensitivity and NPV add value to the negative test result, indicating a very low risk of developing cervical disease and allowing longer screening intervals. However, because of frequent transient HPV infections among younger women, HPV testing is generally recommended for primary cervical cancer screening only among women 30 years old and older (21) .
Screening for cervical cancer using hrHPV testing instead of Pap aims at risk recognition, i.e. finding true or potential disease. The high NPV of hrHPV testing allows longer screening intervals with similar or lower risk of developing CIN3 + lesions as compared with Pap No cytological sample was taken on the HPV sampling visit. test (9, 11, 22) . The lower NPV of cytology among women below 30 years of age shows that a negative Pap result does not necessarily indicate the absence of the disease. Based on different studies, screening intervals of as much as 5-10 years could be considered in programs based on hrHPV screening (9) (10) (11) (12) 22, 23) . The effectiveness using primary HPV screening with cytology triage and five-year screening intervals has been convincingly shown in the Finnish national screening program (22) . Mild lesions are often associated with low-risk HPV types, which cause a very low or non-existing risk for CIN3 + lesions and cervical cancer (24) . The HPV assays evaluated in this study detect only high-risk HPV types. Thus lesions caused by low-risk types would have remained negative, although HC2 is known to cross-react with lrHPV types (25) . The cross-reactivity of the Aptima assay has not yet been assessed in large clinical materials. Five CIN2 cases remained negative using the HC2 test and four using the Aptima assay. Some CIN2 lesions are caused by low-risk genotypes with low risk of progression into cervical cancer (21, 24, 26, 27) , which may partially explain this finding. Overall, the sensitivity of hrHPV testing for CIN2 + was higher than that of Pap, and thus fewer severe cases will be missed by hrHPV than by Pap testing. Importantly, all CIN3 + cases were found positive with both hrHPV assays in all age groups.
Consensus prevails on HPV16 being the genotype of highest risk, followed by HPV18 and HPV45 and possibly some other high-risk types. This was also seen in our study material where the frequency of HPV16 and HPV18/45 positivity clearly increased towards more severe disease, whereas other hrHPV types were found in all histological groups except for the two carcinomas. The overall prevalence of HPV16 (10.2%) and HPV18/45 (4.6%) was fairly low in our study population but was in agreement with the previously published genotype distribution in the Finnish screening population, showing a lower prevalence of genotypes 16, 18 and 45 in particular (28) . The Aptima Genotype Assay provides a triaging option for HPV-positive women in the future but as yet the European guidelines for cervical cancer screening do not specifically recommend the inclusion of HPV genotyping in patient management (29) .
Previous studies have shown better specificity with Aptima than with HC2 (15) (16) (17) (30) (31) (32) . In both triage of ASC-US and LSIL, Aptima is as sensitive but more specific than HC2 for detecting cervical pre-cancer. Only Aptima has been considered useful in triage of LSIL (5). In the present study we were not able to reproduce this difference, instead the specificity was very similar for both hrHPV methods. As we found the HC2 and Aptima assays perform equally well in detecting high-grade cervical lesions, the practical test properties may become decisive when choosing a HPV test for clinical use. These include the hands-on time required, additional testing opportunities including genotyping, as well as the required throughput and instrumentation available in the laboratory. Automation is also available for HC2 (Rapid Capture System and Hybrid Capture 2 Modular System, Qiagen), which diminishes the amount of manual work and shortens turn-around time. The benefits of Aptima with the Panther system include flexible throughput, reduced hands-on time and full automation. The inclusion of an automated and highly sensitive hrHPV testing method, such as Aptima, could be used to increase the efficiency of cervical cancer screening and further reduce cervical cancer incidence.
The guidelines and criteria for HPV testing in primary cervical cancer screening have taken into account only DNA-based tests so far (21, 33) , but the Aptima HPV assay also fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical cancer screening (34) . Our study shows that the performance of mRNA-based Aptima assay did not differ from the widely used and well-studied DNA-based HC2 test. Our data contribute to the growing evidence base on the Aptima HPV mRNA assay and indicate that it could be used for the triage of patients with the indication of HPV-associated cervical disease. Table S1 . Sensitivity, specificity, and positive and negative predictive values (95.0% CI) of Pap test in the detection of CIN2 + in age groups below and above 30 years of age (n = 330 samples with histology) for two different thresholds of test positivity (ASC-US + and LSIL + ). Table S2 . Sensitivity, specificity, and positive and negative predictive values (95.0% CI) of the hrHPV tests in the detection of CIN2 + in age groups below and above 30 years of age (n = 330 samples with histology). Table S3 . Genotyping results and histological findings of Aptima hrHPV-positive samples.
